OncoSil Medical |
High $0.01 |
Low $0.01 |
Trades 21 |
Turnover $70,215 |
Volume 5,851,219 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (13-Nov) $23,857,560 (1,393rd) |
Close (30-Jun) $0.012 |
Volume (30-Jun) 5,851,219 |
Shortsold (6-Nov) 66 (0.00%) (659th) |
|
52w High $1.64 |
52w Low $0.370 |
P/E 4.51 |
EPS -0.48 |
Oral presentation at The Mayo Clinic IMPACT Course
OSL released this announcement to the ASX on 24 April 2023, 9:16. The announcement is marked as price sensitive, and is 2 page(s) in length and 223.77kb in size.
You can view all announcements from OSL and see how they appear on a price chart on the announcements page.
At the date of this announcement, OSL was 0.681% short sold according to ASIC data. It was ranked the 246th most shorted stock on the ASX. It remains ranked 659th as of the latest reported data (06 November 2026).
| Other Recent Announcements from OSL | |
|---|---|
| Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer | 30 June 2023, 9:49 |
| Notification of cessation of securities - OSL | 29 June 2023, 17:51 |
| Ethics Committee Approves PANCOSIL Clinical Trial | 5 June 2023, 9:31 |
| Oral presentation at The Mayo Clinic IMPACT Course | 24 April 2023, 9:16 |
| Further commercial milestones achieved in Spain | 24 April 2023, 9:15 |
| Extension of Closing Date of Entitlement Offer | 21 April 2023, 16:02 |
| Additional Binding Commitment Received for Entitlement Offer | 21 April 2023, 10:02 |
If you were already registered, log in here.